Mahrouf-Yorgov Meriem, Marie Nicolas, Borderie Didier, Djelidi Raja, Bonnefont-Rousselot Dominique, Legrand Alain, Beaudeux Jean-Louis, Peynet Jacqueline
EA 3617 Biochimie radicalaire et atteintes vasculaires, Université Paris Descartes, UFR des Sciences Pharmaceutiques et Biologiques, 4, avenue de l'Observatoire, F75006 Paris, France.
Metabolism. 2009 Apr;58(4):525-33. doi: 10.1016/j.metabol.2008.11.012.
Overactivation of poly(adenosine diphosphate-ribose) polymerase (PARP), an enzyme involved in cellular response to DNA injury resulting from oxidative and nitrosative stress, is considered to play a key role in the pathogenesis of diabetes complications by promoting numerous vascular dysfunctions. In this study, we examined the ability of metformin, which was reported to possess intrinsic vasculoprotective properties independently of its antihyperglycemic effects, to inhibit PARP activation induced by high glucose concentrations in bovine aortic endothelial cells; and we investigated the potential mechanisms involved in this inhibition. The PARP activity was measured by cellular enzyme-linked immuno-specific assay (CELISA) method; cell poly(ribosyl)ated protein polymer accumulation was evaluated by immunofluorescence. Peroxynitrite anion productions were determined using dihydrorhodamine 123 fluoroprobe; and expression of p47phox subunit of nicotinamide adenine dinucleotide phosphate (NAD(P)H) oxidase was analyzed by Western blot in the absence and presence of protein kinase C and NAD(P)H oxidase inhibitors (calphostin and diphenyleneiodonium chloride, respectively). Our data showed that a therapeutically relevant concentration of metformin (5.10(-5) mol/L) was able to abolish PARP activation, to reduce poly(ribosyl)ated protein polymer accumulation, to decrease intracellular peroxynitrite anion level, and to reverse the overexpression of p47phox in bovine aortic endothelial cells stimulated by 25 mmol/L glucose in a similar manner to that of calphostin or diphenyleneiodonium chloride. Taken together, these results suggest that metformin could inhibit glucose-induced PARP activation through blockade of a protein kinase C-dependent NAD(P)H oxidase activation pathway. We propose that some of the beneficial effects of metformin on vascular endothelial cell functions in diabetes may be related to its inhibitory effect on PARP overactivation and its deleterious consequences.
聚(腺苷二磷酸 - 核糖)聚合酶(PARP)过度激活被认为在糖尿病并发症发病机制中起关键作用,该酶参与细胞对氧化应激和亚硝化应激导致的DNA损伤的反应,它会引发多种血管功能障碍。在本研究中,我们检测了据报道具有独立于其降糖作用的内在血管保护特性的二甲双胍抑制高糖浓度诱导的牛主动脉内皮细胞PARP激活的能力;并研究了这种抑制作用的潜在机制。通过细胞酶联免疫特异性测定(CELISA)方法测量PARP活性;通过免疫荧光评估细胞聚(核糖基)化蛋白聚合物积累。使用二氢罗丹明123荧光探针测定过氧亚硝酸盐阴离子产生;在存在和不存在蛋白激酶C和烟酰胺腺嘌呤二核苷酸磷酸(NAD(P)H)氧化酶抑制剂(分别为钙泊三醇和二苯基碘鎓氯化物)的情况下,通过蛋白质印迹分析NAD(P)H氧化酶的p47phox亚基的表达。我们的数据表明,治疗相关浓度的二甲双胍(5×10⁻⁵mol/L)能够消除PARP激活,减少聚(核糖基)化蛋白聚合物积累,降低细胞内过氧亚硝酸盐阴离子水平,并逆转25 mmol/L葡萄糖刺激的牛主动脉内皮细胞中p47phox的过表达,其作用方式与钙泊三醇或二苯基碘鎓氯化物相似。综上所述,这些结果表明二甲双胍可通过阻断蛋白激酶C依赖性NAD(P)H氧化酶激活途径来抑制葡萄糖诱导的PARP激活。我们提出,二甲双胍对糖尿病血管内皮细胞功能的一些有益作用可能与其对PARP过度激活及其有害后果的抑制作用有关。